This page covers the subject in men.
Overview
Testosterone is a steroid hormone. In men nearly all of it is made in the testes, on a signal from the pituitary gland. It drives the changes of puberty and sperm production, and through adult life it helps maintain muscle, bone and red blood cells. Women make it too, in much smaller amounts. The trials cited below enrolled men, which is why this page is about men.
Most of what gets said about testosterone concerns a narrower question: what happens when the level is low, and whether raising it helps. That question has better answers than it did ten years ago. Since 2016, large placebo-controlled trials have tested testosterone treatment in several thousand men with low levels and reported what improved, what did not, and what went wrong[1][2][3]. Those trials, and the two clinical guidelines that doctors in the United States work from[4][5], are the basis for this page.
Why it matters
Low testosterone with symptoms is a medical condition called hypogonadism. It can start in the testes or in the pituitary and hypothalamus that signal to them, and the Endocrine Society guideline recommends looking for the cause once a deficiency is confirmed[4].
Levels also drift down with age. The Baltimore Longitudinal Study of Aging measured testosterone in stored samples from 890 men and found a steady decline with age that illness and medication did not account for. By the total testosterone cutoff that study used, about 20% of men over 60, 30% of men over 70 and 50% of men over 80 had levels in the hypogonadal range[6].
A low number is common, then, and a low number does not always come with symptoms. The European Male Ageing Study surveyed 3,369 men aged 40 to 79 about their health and measured their morning testosterone. Fatigue, depression and difficulty with vigorous activity were statistically related to the level, but only three symptoms formed a consistent pattern with low testosterone, and all three were sexual: fewer morning erections, low desire and erectile dysfunction[7].
Tiredness, poor concentration and low libido are the complaints most often blamed on testosterone. The authors of a sleep study made the point that all of them can be produced by sleep deprivation in healthy people[8]. The Endocrine Society recommends making the diagnosis only in men who have both symptoms and consistently low readings[4], and the urologists' guideline builds its assessment on levels, symptoms and signs together[5].
How it works
The hypothalamus releases a hormone called GnRH, which tells the pituitary to release two more. LH signals the testes to make testosterone. FSH supports sperm production. Testosterone in the blood feeds back on the brain and turns that signal down. This loop is why testosterone taken from outside the body shuts down the body's own production, sperm included.
In the bloodstream most testosterone is bound to proteins, chiefly sex hormone-binding globulin (SHBG) and albumin, and a small share circulates free. A standard blood test reports total testosterone, bound and free together. When the total sits near the lower limit, or when something has altered SHBG, the Endocrine Society guideline recommends measuring or calculating free testosterone as well[4].
Some testosterone is converted to estradiol, an estrogen, and part of what gets credited to testosterone is estradiol's work. In a 16-week experiment, 400 healthy men aged 20 to 50 had their own hormone production suppressed and were then given testosterone gel at a range of strengths or a placebo, about half of them with a drug that blocks the conversion to estradiol. The loss of lean mass, muscle size and strength came from the lack of testosterone, the gain in body fat came mainly from the lack of estradiol, and sexual function declined when either was missing. The amount of testosterone needed to hold each of these steady varied widely from man to man[9].
Levels move through the day. In men aged 30 to 40, testosterone at 4 pm was 20 to 25% lower than at 8 am, and the gap narrowed to about 10% by age 70[10]. Sleep moves them too. Ten healthy young men, average age 24, who were held to five hours in bed a night for a week had daytime levels 10 to 15% lower than when they were rested[8].
What the evidence suggests
The treatment results below come from men aged 45 and over whose low or low-normal testosterone was confirmed by blood tests. They do not describe what testosterone does for a man whose level is normal.
Sexual function
In the Testosterone Trials, 790 men aged 65 and over with levels below 275 ng/dL and symptoms used testosterone gel or a placebo gel for a year. Sexual activity, desire and erectile function improved on testosterone, and the authors described the benefit as moderate[1][11].
Mood, energy and physical function
In the same trials testosterone slightly improved mood and depressive symptoms. It did not improve energy, it did not improve walking distance in the men enrolled because they walked slowly, and it did not improve cognitive function[1][11].
Blood and bone
Testosterone raises hemoglobin. Among the 815 men who entered the TRAVERSE trial with anemia, the anemia had corrected at six months in 41.0% of those on testosterone and 27.5% of those on placebo[12].
Bone is less clear. In the Testosterone Trials, treatment increased bone density and estimated bone strength[11]. In TRAVERSE, which was far larger and counted actual fractures, 3.50% of men on testosterone and 2.46% of men on placebo had a fracture over a median of about three years. The authors concluded that testosterone did not lower fracture risk[13].
Blood sugar
T4DM enrolled 1,007 Australian men aged 50 to 74 with a large waist, a testosterone level at or below 14 nmol/L, and either impaired glucose tolerance or newly diagnosed type 2 diabetes. All of them joined a lifestyle program, and half received testosterone injections for two years while half received placebo. At the end, 12% of the testosterone group and 21% of the placebo group met the glucose test threshold for type 2 diabetes[2]. The same trial recorded a common side effect, covered under hematocrit in the next section.
Weight loss raises testosterone
The link between body weight and testosterone runs in both directions. A meta-analysis of 24 studies found that weight loss raised testosterone in men with obesity, by more after bariatric surgery than after a low-calorie diet, and that the amount of weight lost was the best predictor of the rise[14]. In the European Male Ageing Study, men who lost weight over about four years saw testosterone rise and men who gained weight saw it fall[15].
Risks and limits
Fertility
Testosterone from outside the body suppresses sperm production, reliably enough that it has been tested as a contraceptive. In a World Health Organization study, 271 fertile men received weekly testosterone injections, and by six months 65% had no sperm in three consecutive semen samples. After the injections stopped, sperm concentration took a median of 3.7 months to return to 20 million per milliliter and 6.7 months to return to each man's own starting level[16]. The Endocrine Society recommends against starting testosterone in men who plan to conceive in the near term[4].
Hematocrit
Testosterone raises the red blood cell count, and hematocrit is the share of the blood those cells make up. In T4DM, hematocrit rose above 54% in 22% of the men on testosterone and 1% of the men on placebo, and the authors wrote that the rise might limit treatment[2]. The Endocrine Society's monitoring plan includes hematocrit, and it lists an elevated hematocrit among the reasons to hold off on treatment[4].
Heart and circulation
Whether testosterone treatment raises the risk of heart attack and stroke was an open question for years. The Testosterone Trials were too small to answer it[1]. TRAVERSE was built for it: 5,246 men aged 45 to 80 with symptoms, two fasting readings below 300 ng/dL, and either existing cardiovascular disease or a high risk of it, followed for an average of 33 months. A major cardiac event occurred in 7.0% of the testosterone group and 7.3% of the placebo group, which met the trial's test for noninferiority. The same trial recorded more atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group. It was funded by AbbVie and other companies[3].
Who the guideline says should not start
The Endocrine Society recommends against starting testosterone in men with breast or prostate cancer, a prostate nodule or raised PSA that has not been evaluated by a urologist, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, a heart attack or stroke in the past six months, or a tendency to form blood clots[4].
What these trials cannot say
The treatment trials on this page enrolled men of 45 and over with confirmed low or low-normal levels, and the largest followed them for about three years. They say nothing about younger men, about men with normal levels, or about use over decades.
The research
Most of this page rests on randomized, placebo-controlled trials in men: the Testosterone Trials (790 men, one year)[1], T4DM (1,007 men, two years)[2] and TRAVERSE (5,246 men, about three years)[3]. The reference range comes from four cohort studies whose measurements were recalibrated against a single standard at the CDC[17].
The findings on age, symptoms, body weight and time of day come from observational studies. Those can show that two things move together. They cannot show that one causes the other. The sleep experiment involved ten men, and its authors called it a small convenience sample[8].
Three of the sources summarize other research: the two guidelines and one review of the Testosterone Trials. They are marked as such in the source list. No animal or laboratory studies are cited on this page.
What gets measured
Total testosterone
This is the first test. The Endocrine Society recommends a fasting morning sample measured with an accurate assay, and a second fasting morning sample to confirm a low result before any diagnosis[4]. The timing matters because of the daily swing. In one study, 17 men had at least one afternoon reading below 300 ng/dL, and 9 of them had normal readings at every morning visit[10].
The reference range
For healthy, non-obese men aged 19 to 39, the harmonized range is 264 to 916 ng/dL, with a median of 531. The same study found that much of the disagreement between earlier studies came from differences between assays[17], which is a reason to read a result against the range printed on that laboratory's own report.
Free testosterone and SHBG
The guideline recommends these when the total is near the lower limit or when a condition that changes SHBG is present. It specifies equilibrium dialysis or an accurate formula for the free value[4].
LH and FSH
Once low testosterone is confirmed, these two pituitary hormones help show where the problem sits. High LH and FSH alongside low testosterone point to the testes. Low or normal LH and FSH alongside low testosterone point to the pituitary or hypothalamus. Finding the cause is part of the guideline's recommended workup[4].
Hematocrit and prostate checks
These are the safety checks once treatment has started. The Endocrine Society's monitoring plan covers symptoms and side effects, testosterone and hematocrit levels, and an evaluation of prostate cancer risk during the first year[4].
Questions worth asking
When a blood test comes back low, these are the questions the guidelines have a doctor work through. They are fair ones to bring to an appointment.
- Was the sample taken in the morning, fasting, and has it been repeated? A single reading is not a diagnosis[4].
- Are there symptoms that go with it? In the large European study, the ones that tracked with low testosterone were sexual[7].
- Has anything else moved the number? Short sleep and weight gain have both been linked to lower readings[8][15].
- What is the cause? The guideline recommends finding out before treatment starts[4].
- Is a pregnancy planned? Testosterone treatment suppresses sperm production[16].
- If treatment starts, what will be monitored, and how often?
This page gives no doses. Whether to treat, and with what, is a decision for a doctor who has the test results and the medical history to hand.
Related guides
- Sleep durationHow long people habitually sleep, followed in cohorts of millions. Both short and long sleep track with earlier death and more heart disease, with the lowest risk around seven hours. Short sleep has a plausible mechanism; long sleep is probably a marker of illness.Established
- Sleep restrictionWhat happens when healthy people are made to sleep less, in the lab. Two weeks at six hours a night degrades attention as much as two nights with no sleep, and the people affected do not feel it. An extra hour improved short sleepers' sleep but, in one trial, not metabolism.Established
- Resistance trainingLifting against resistance, followed in cohorts of hundreds of thousands. Any amount is associated with 15 to 20% lower mortality, the lowest risk sits around an hour a week, and the benefit adds to aerobic exercise. Above a couple of hours a week the curve flattens or turns.Established
- Tongkat aliA Southeast Asian root sold to men for testosterone. Five small trials pooled show testosterone rising; two erection trials pooled show nothing. EFSA declined to clear the extract after a DNA-damage signal, and 26% of Malaysian products once tested over the mercury limit.Early clinical
- FenugreekA kitchen spice whose seed extracts are sold to men for testosterone. Seven trials pooled show a small rise in total testosterone (SMD 0.32), most of it from branded extracts with manufacturer involvement. The better-founded effect is on blood sugar in people with diabetes.Early clinical
- ShilajitA tar-like resin from Himalayan rock, used in Ayurveda for centuries. One small 90-day trial raised testosterone in men aged 45 to 55; one 8-week trial reduced strength loss after fatigue. Both used the same purified extract. Raw resin has tested over heavy-metal limits.Early clinical
- Fadogia agrestisA Nigerian shrub sold to men on the strength of a 2005 rat study. There is no human trial of any kind. The same rat lab found testicular changes at every dose after 28 days and membrane damage in liver and kidney. It is here so nobody has to find that out after buying it.Preclinical
- GonadorelinThe native GnRH decapeptide. An established diagnostic and fertility agent whose popular use, restarting suppressed testosterone production, is the use with the least evidence behind it.Established
- Kisspeptin-10 (KP-10)The upstream trigger of the reproductive axis, with genuine ongoing academic human research. One of the more scientifically respectable entries at this end of the ladder.Early clinical
Sources
17- 1
Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men The New England Journal of Medicine, 2016.
The Testosterone Trials: 790 men aged 65 and over, one year, placebo-controlled.
Randomized trialPMID 26886521doi:10.1056/NEJMoa1506119
- 2
Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial The Lancet Diabetes & Endocrinology, 2021.
1,007 men at six Australian centers, two years. Funders included Bayer and Eli Lilly.
Randomized trialPMID 33338415doi:10.1016/S2213-8587(20)30367-3
- 3
Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy The New England Journal of Medicine, 2023.
TRAVERSE: 5,246 men, placebo-controlled. Funded by AbbVie and others.
Randomized trialPMID 37326322doi:10.1056/NEJMoa2215025
- 4
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology & Metabolism, 2018.
The Endocrine Society's recommendations on diagnosis, treatment and monitoring.
Clinical guidelinePMID 29562364doi:10.1210/jc.2018-00229
- 5
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline The Journal of Urology, 2018.
The American Urological Association's guideline for the same condition.
Clinical guidelinePMID 29601923doi:10.1016/j.juro.2018.03.115
- 6
Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging The Journal of Clinical Endocrinology & Metabolism, 2001.
890 men followed over time. Measured by an older immunoassay method.
Observational studyPMID 11158037doi:10.1210/jcem.86.2.7219
- 7
Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men The New England Journal of Medicine, 2010.
The European Male Ageing Study: 3,369 men aged 40 to 79 at eight centers.
Observational studyPMID 20554979doi:10.1056/NEJMoa0911101
- 8
Leproult R, Van Cauter E Effect of 1 week of sleep restriction on testosterone levels in young healthy men JAMA, 2011.
A laboratory sleep experiment in ten men, each compared with his own rested state. Published as a research letter.
Trial without a control groupPMID 21632481doi:10.1001/jama.2011.710
- 9
Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men The New England Journal of Medicine, 2013.
400 healthy men, 16 weeks. An experiment in physiology, not a treatment trial.
Randomized trialPMID 24024838doi:10.1056/NEJMoa1206168
- 10
Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men The Journal of Clinical Endocrinology & Metabolism, 2009.
66 men aged 30 to 80, sampled on three mornings and three afternoons.
Observational studyPMID 19088162doi:10.1210/jc.2008-1902
- 11
Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons From the Testosterone Trials Endocrine Reviews, 2018.
The trial investigators' summary of all seven Testosterone Trials.
ReviewPMID 29522088doi:10.1210/er.2017-00234
- 12
Pencina KM, Travison TG, Artz AS, et al. Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial JAMA Network Open, 2023.
A study nested within TRAVERSE.
Randomized trialPMID 37889486doi:10.1001/jamanetworkopen.2023.40030
- 13
Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone Treatment and Fractures in Men with Hypogonadism The New England Journal of Medicine, 2024.
A subtrial of TRAVERSE: 5,204 men, median follow-up 3.19 years.
Randomized trialPMID 38231621doi:10.1056/NEJMoa2308836
- 14
Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis European Journal of Endocrinology, 2013.
24 studies of diet or bariatric surgery.
Meta-analysisPMID 23482592doi:10.1530/EJE-12-0955
- 15
Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study European Journal of Endocrinology, 2013.
2,736 men aged 40 to 79, followed for a mean of 4.4 years.
Observational studyPMID 23425925doi:10.1530/EJE-12-0890
- 16
World Health Organization Task Force on Methods for the Regulation of Male Fertility Contraceptive efficacy of testosterone-induced azoospermia in normal men The Lancet, 1990.
271 fertile men at ten centers in seven countries. Every participant received testosterone.
Trial without a control groupPMID 1977002
- 17
Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe The Journal of Clinical Endocrinology & Metabolism, 2017.
9,054 men across four cohorts, recalibrated to one reference method.
Observational studyPMID 28324103doi:10.1210/jc.2016-2935